MedPath

efficacy of ingenol mebutate with comparison to podophyllin on treatment of patients with anogenital wart.

Phase 2
Recruiting
Conditions
Genital wart.
Anogenital (venereal) warts
Registration Number
IRCT20180715040482N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with untreated anogenital persistent to therapy wart

Exclusion Criteria

Immunosuppressed patients
Patients with drug reaction
Patients with other sexually transmitted diseases like herpes in the anogenital area
Pregnancy and lactation
Under 18 y/o
Treatment with other choices like cryotherapy or imiquimod in the last 4 weeks

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients with untreated or resistant anogenital warts. Timepoint: Following up at 1,2,3 weeks and 1,3,5 months after the firs treatment. Method of measurement: Physical examination.
Secondary Outcome Measures
NameTimeMethod
The frequency of repeating treatment until complete cure. Timepoint: Weekly follow up until 3 weeks, then follow up at 1,3 and 5 months after the first course of treatment. Method of measurement: Physical examination.;Duration of disease. Timepoint: The number of months the warts developed. Method of measurement: History.;Number of warts. Timepoint: Number of warts at the beginning of treatment and follow up. Method of measurement: Clinical counting.;Side effects after treatment. Timepoint: 7, 14, 21, 30,90 and 180 days after treatment. Method of measurement: Inspection and clinical examination.
© Copyright 2025. All Rights Reserved by MedPath